Both the loss of CARM1 and the mutation of the CARM1 methylation site on NFIB in the TKO mouse model resulted in dramatically reduced lung tumor burden, as well as the levels of the tumor cell proliferation biomarker, phospho-H3 (Fig. 3h–j). This evidence concerns the gene CARM1 and neoplasm.